No, you are not the only one who thinks it's odd. But sometimes the best picks are those peers and analysts agree with only AFTER it's taken off. Sometimes it's just odd; CYDY against all odds.

I couldn't find anything negative as to the scientific and medical results and potential of Leronlimab. So safe, so effective, so many advantages over HAART, so many indications. Have there been strategical mistakes and has the company been mis-managened on the financial side? Hell, yes! (IMHO)

Anyway, this should be a moot question by Christmas, if BLA is submitted and deal closed as promised. I agree with Fortuno and others that BLA only will not move the SP. We need that deal to get better financing and escape that death spiral of shares and warrants... Trials need to ramp up, with more than one or two (or none: Hello, GvHD!) patients enrolled every month or two.

If no BLA and deal by end of December, I will have lost all faith in management and BOD and their ability to execute; but even in this case, I wouldn't sell, because, well, with even a colossal mess-up with 2b shares or in Ch 11, the company is worth way beyond .48 (or $1, $2 etc.).